Source:Instrument Family,Reproduction without authorization is prohibited, and reproduction is allowed 24 hours later.
December 1, 2023GE Healthcare China's First Batch of Locally Produced Cyclotrons Rolled Off the Production Line at Chengdu BaseThis is another significant milestone in GE Healthcare's comprehensive localization strategy in China.GE Healthcare China's First Batch of Nuclear Medicine Cyclotrons
It is reported that,This project is a major investment in China's supply chain landscape by GE Healthcare after it became an independent listed brand in January this year. From initiation to product rollout, it took less than a year, and the product delivery speed has been tripled.Benefiting clinical users in China, supporting discipline development and precise diagnosis and treatment of serious diseases, and further accelerating the advancement of China's high-end medical device manufacturing towards ultra-high-end.The "China Speed" demonstrated by the first batch of domestically produced cyclotrons rolling off the production line benefited from the excellent business environment and support in Chengdu, Sichuan.This further demonstrates GE Healthcare's commitment and determination to deeply invest in China.
The First Batch of Chinese-produced Cyclotrons Rolled Off the Production Line
It is reported that nuclear medicine is an emerging discipline in modern medicine, playing a key role in precision healthcare. It can provide earlier insights into molecular-level information of diseases and assist clinical research in overcoming major diseases in neurology, oncology, and cardiology, such as Alzheimer's disease. In recent years, the signal for the development of nuclear medicine in China has become increasingly evident. The "Medium- and Long-term Development Plan for Medical Isotopes (2021-2030)" explicitly states the need to increase the independent research and development efforts of high-end diagnostic and treatment equipment.Accelerate the localization process of key core components and complete machines in China, and form the development and mass production of medium and high energy cyclotrons.The cyclotron is a key device in the integrated precision diagnosis and treatment solution of nuclear medicine. A stable supply produced in China will provide infrastructure for the construction of nuclear medicine specialties and precision diagnosis and treatment based on nuclear medicine.The cyclotron, combined with chemical synthesizers, SPECT/CT, PET/CT (MR), and related software and hardware, constitutes GE Healthcare's One MI integrated molecular imaging solution for clinical research.
This solution forms a complete closed-loop nuclear medicine ecosystem from radionuclide production, drug synthesis, and image data acquisition to drug application and supporting radionuclides, including tracer production equipment, MI tracers, PET and SPECT scanners, and digital solutions.Predict the molecular status of diseases earlier and more accurately, enabling clinicians to detect lesions at an earlier stage and develop personalized diagnosis and treatment plans, thereby assisting clinical research in overcoming major diseases in the fields of neurology, oncology, and cardiology.October 2022,GE Healthcare High-Level Industrial Project Signed and Landed in Chengdu High-Tech Zone,And was launched in May this year at the Chengdu Tianfu International Bio City. Its first phaseFocus on the production and manufacturing of key equipment for nuclear medicine molecular imaging — cyclotrons, promoting the innovative development of the precision medical industry chain centered on nuclear medicine imaging equipment.Chen Heqiang, Vice President of GE Healthcare China and General Manager of China Supply Chain, stated: "The foundation of precision medicine is precise diagnosis, and nuclear molecular imaging is the core for achieving precise diagnosis."GE Healthcare highly values the opportunities presented by the development of Western China. It is intensifying cooperation in areas such as medical technology innovation, high-end equipment manufacturing, and the construction of modern service hubs, promoting the innovative and integrated development of the industrial and supply chains for advanced nuclear medicine equipment and precision healthcare."Support the Healthy Sichuan Action strategy, quickly respond to the demand for nuclear medicine technology equipment in the new medical infrastructure, and provide services for precise diagnosis and treatment of patients."It is reported that GE Healthcare China will further advance the second-phase plan in the future. Relying on Chengdu's advantages as a "Belt and Road" node city and its precision medicine industry ecosystem, GE Healthcare will collaborate with partners to build innovation and collaboration centers. Additionally, it will introduce multiple upstream, downstream, and industrial ecosystem partners to create an industry cluster.Build a reliable, secure, and resilient domestic supply chain system to drive the high-quality development of advanced medical equipment and boost the establishment and strengthening of the high-end medical device industry chain.It is worth mentioning that,On the same day, Huang Qiang, Deputy Secretary of the Sichuan Provincial Party Committee and Governor of Sichuan Province, met with Zhang Yihao, Global Executive Vice President of GE Healthcare, President and CEO of GE Healthcare China, and his entourage in Chengdu.Huang Qiang congratulated GE Healthcare on the first batch of cyclotron products just rolled off the production line in Chengdu.At the same time, it is hoped that GE Healthcare will seize the opportunity, deepen its presence in Sichuan, accelerate the construction of China's precision medical industrialization base, and increase the intensity of industrial project layout.Actively explore the establishment of a research and development center in Sichuan, fully play the leading role in the industry, gather and drive more upstream and downstream supporting enterprises to invest and start businesses in Sichuan, and strengthen cooperation with Sichuan's scientific research institutes, medical institutions, and pharmaceutical enterprises.In response, Zhang Yihao replied,GE Healthcare has high expectations for the development prospects of Sichuan and will continue to increase investment in research and development in the region, deepen and expand areas of cooperation, and play a leading role as a key enterprise in the industrial chain.To help accelerate the development of precision medicine industry ecosystems and make greater contributions to the high-quality development of Sichuan's pharmaceutical and healthcare sector.Focus on Nuclear MedicineGE Healthcare Strengthens Layout in Western ChinaData shows,The Chengdu base is the first precision healthcare industrialization project that GE Healthcare has laid out in western China in recent years.The cyclotron rolled out this time leverages GE Healthcare's over 30 years of global technological advantages while integrating China's leading manufacturing processes. It demonstrates the collaborative efforts of GE Healthcare's global supply chain and serves as a representative work in jointly building a "win-win chain" for high-quality development of global medical devices through consultation and collaboration. Concurrently, with the rollout of the first batch of cyclotrons, the Phase I goal of the Chengdu Precision Medicine Industrialization Base, which focuses on key equipment for nuclear medicine molecular imaging, has been achieved.
Rendering of GE Healthcare China Precision Medicine Industrialization Base
In fact,As early as 2011, GE's first global Customer Collaboration Innovation Center, namely the GE China Innovation Center (CIC), was established in Chengdu, Sichuan. Meanwhile, the GE Healthcare China Customer Service Remote Command Center also landed in Chengdu.In promoting innovation activities in China, especially in the central and western regions, advancing GE's global innovation strategy upgrade, and promptly responding to medical customers' equipment maintenance and repair needs, it has made significant contributions. After more than a decade of development, Chengdu CIC has become GE Healthcare's leading innovation platform in China.In October 2022, GE Healthcare further increased its investment.Signed a cooperation agreement with Chengdu High-tech Zone, announcing the official landing of GE Healthcare China's precision medicine industrialization base project.According to reports,The first phase of the Chengdu Precision Medicine Base project will focus on the domestic production of key equipment for nuclear medicine molecular imaging, specifically cyclotrons, promoting the innovative development of a precision medicine industry chain centered on the localization of nuclear medicine imaging equipment.The foundation of precision medicine is precise diagnosis, and nuclear molecular imaging is at the core of achieving accurate diagnosis. With the development of Chengdu's precision medicine base, it will undoubtedly provide significant support to the precise diagnosis and treatment of major diseases such as cancer and cardiovascular and cerebrovascular conditions in China, offering better services to both doctors and patients in the country.As a medical enterprise with a century-long history of innovation in molecular imaging, GE Healthcare deeply understands,The cyclotron is a key device in the integrated imaging technology solution for nuclear medicine.A stable supply of domestically produced medical equipment will provide the infrastructure for China's "one county, one department" initiative, the development of nuclear medicine specialties, and the implementation of integrated precision diagnosis and treatment in nuclear medicine for major diseases.Promoted the innovation and integrated development of the industrial chain and supply chain for the localization of high-end nuclear medicine equipment and precision medical care in China.From continuously increasing investment in Sichuan, and constantly strengthening cooperation in medical technology innovation, high-end equipment manufacturing, and the construction of modern service hubs, it can be observed that,GE Healthcare is continuously deepening its China strategy of "comprehensive production in China, limitless innovation, and win-win cooperation," meeting the growing and diverse needs of high-end, grassroots, and non-public healthcare markets from all aspects including products, channels, services, and supply chains.Revenue of 4.8 billion achieved in Q3 2023Fastest Growing Performance in ChinaGE Healthcare, as a leading global innovator in precision medicine, was spun off from GE Group, a Fortune 500 company, in January this year and successfully listed on the NASDAQ in the United States. Its business scope covers four major segments: medical imaging, ultrasound, life care, and diagnostic pharmaceuticals.In terms of performance, on October 31, 2023, GE Healthcare's announced financial results showed,In Q3 2023, GE Healthcare's revenue was $4.822 billion, a year-on-year increase of 5%.In terms of specific performance, Q3 2023,GE Healthcare's imaging products achieved revenue of $2.635 billion, a year-on-year increase of 5%, accounting for 55% of total revenue.Its products include CT, MR, molecular imaging, X-ray, women's health, image-guided therapy, enterprise imaging software, services, and digital solutions. Among them,Revenue growth was primarily driven by molecular imaging, CT, and MRI, benefiting from improved supply chains, pricing, and new product launches.Ultrasound segment achieves revenue of 8.15 billion USD, nearly flat compared to 8.23 billion USD in the same period last year, accounting for 17% of total revenue.Its products include controllers and probes, handheld devices, intraoperative imaging systems, visualization software, services, and digital solutions. Its EBIT margin was 22.0%, down from 25.6% in the same period last year, mainly due to investment plans, inflation, and increased production efforts.The Life Care segment achieved revenue of $7.64 billion, representing a 9% increase year-over-year, accounting for 16% of total revenue.Products involve life detection, anesthesia and respiratory care, maternal and child care, heart disease diagnosis, as well as consumables, services, and digital solutions.AndPharmaceutical Diagnostics achieved revenue of $5.89 billion in Q3 2023, representing a 13% increase year-over-year and accounting for 12% of the company's total revenue.Products include contrast agents and radiopharmaceuticals, as well as enhanced imaging diagnostics.Notably, in Q3 2023,GE Healthcare's revenue in China was $7.19 billion, accounting for 15%, with a year-on-year increase of 8%.Moreover, according to regional division, in GE Healthcare's performance for the first three quarters of 2023,Revenue in China grew the fastest, reaching $21.05 billion, a 12% increase year-over-year.China-Made Medical CyclotronStrong Development MomentumMedical Linear Accelerator (Medical Linear Accelerator), commonly referred to as a medical accelerator, is a medical device used in radiation oncology treatment, specifically for adjuvant therapy (radiotherapy) in radiation oncology.Medical accelerators can generate high-energy electron beams or X-ray beams, which are used to destroy the DNA of cancer cells, preventing their proliferation and growth, thereby achieving the therapeutic goal.The working principle of medical cyclotrons is based on particle physics and electromagnetism. It accelerates electrons within the metal conduits inside the accelerator, causing them to move at speeds close to the speed of light. When these high-speed electrons strike a target inside the patient’s body, they generate high-energy X-rays. These X-rays can precisely target cancer cells, causing DNA damage that prevents the cells from further dividing and growing. Currently,Medical cyclotrons in China are mainly divided into two categories: proton therapy systems and heavy ion therapy systems.As a high-tech medical device, the upstream raw materials of medical cyclotrons mainly include electronic components, magnets, vacuum systems, etc.; the downstream application industries mainly include cancer treatment, nuclear medicine imaging, biophysical research, and other fields.China, as a major user of cyclotrons,In the past decade, the market size of cyclotrons in China has maintained an average annual growth rate of about 20%, and it is expected that the market size will reach more than 2.8 billion yuan by 2025.At present, the cyclotron market in China is mainly concentrated in the four major cities of Beijing, Shanghai, Guangzhou, and Shenzhen, accounting for the majority of the market share in China.73% of the total.The medical cyclotron industry, as the fastest-growing segment in the global high-end medical equipment sector, can be said to...China is in a leading position in the global high-end medical equipment market, with strong industry development momentum.
Then, as a global giant in medical imaging, with the successful rollout of the first batch of cyclotrons produced in China this time,How will GE Healthcare accelerate China's high-end medical device manufacturing towards the ultra-high-end and promote the development of China's nuclear medicine products in the future?We will continue to follow up with reports.
More exciting content
Welcome to follow WeChat Video Channel
BusinessBusiness cooperation email: qxzj@landianyiliao.com
